Date: 2012-12-07
Type of information: Licensing agreement
Compound: Pamorelin® LA (triptorelin)
Company: Debiopharm Group (Switzerland) Dr Reddy\'s (India)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
commercialisation
Action mechanism: Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). In 1982, Debiopharm signed a licensing agreement for triptorelin with Tulane University in the US. Debiopharm has then developed three slow-release formulations (1, 3 and 6 months) of triptorelin pamoate. The 1- and 3-month-formulations have been registered in most countries and are currently available under the names of Trelstar® in North America, Decapeptyl® /Pamorelin® in Europe and Latin America and from now on, of Pamorelin® in India. The 6-month-formulation has been registered and is available in Europe and the US.
Disease: locally advanced or metastatic, hormone-dependent prostate cancer
Details: Debiopharm, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, has announced that Dr. Reddy’s Laboratories Ltd. launched Pamorelin® LA in India for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer on December 3.
Under the terms of the agreement, Dr. Reddy’s acquires exclusive marketing and sales rights for Pamorelin® LA Depot in India. The product is exported in bulk from Debio Recherche Pharmaceutique (Debio R.P.) to Dr. Reddy’s. Pamorelin® LA will be made available primarily to urologists and oncologists across India.
Financial terms:
Latest news:
